# EDGAR Filing Document

**Accession Number:** 0001137360
**File Stem:** 0001752724-23-042754
**Filing Date:** 2023-2
**Character Count:** 16327
**Document Hash:** 26f583f773e7b9590ed37bac0a3e053f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-042754.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001752724-23-042754

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**PERIOD START**: 20230930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VanEck ETF Trust
- **CENTRAL INDEX KEY:** 0001137360
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-10325
- **FILM NUMBER:** 23673569

**BUSINESS ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-293-2000

**MAIL ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VanEck Vectors ETF Trust
- **DATE OF NAME CHANGE:** 20160427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS ETF TRUST
- **DATE OF NAME CHANGE:** 20070312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS TRUST
- **DATE OF NAME CHANGE:** 20050516

## Series and Classes Contracts Data

### VanEck Pharmaceutical ETF (Series ID: S000034409)

| Class ID   | Class Name                | Ticker Symbol   |
|:---|:---|:---|
| C000105867 | VanEck Pharmaceutical ETF | PPH             |

## Nport-Ex

VANECK PHARMACEUTICAL ETF

SCHEDULE OF INVESTMENTS

December 31, 2022 (unaudited)

---

| | | |
|:---|:---|:---|
| | **Number <br>of Shares** | **Value** |
| **COMMON STOCKS: 100.0%** |  |  |
| **Denmark: 5.4%** |  |  |
| Novo Nordisk A/S (ADR) | 232662 | $31488475 |
| **France: 4.5%** |  |  |
| Sanofi (ADR) | 547031 | 26492711 |
| **Israel: 3.5%** |  |  |
| Teva Pharmaceutical Industries Ltd. (ADR) \* | 2276701 | 20763513 |
| **Japan: 4.8%** |  |  |
| Takeda Pharmaceutical Co. Ltd. (ADR) † | 1785206 | 27849214 |
| **Switzerland: 4.9%** |  |  |
| Novartis AG (ADR) | 317655 | 28817662 |
| **United Kingdom: 14.1%** |  |  |
| AstraZeneca Plc (ADR) | 423218 | 28694180 |
| GSK Plc (ADR) | 711082 | 24987422 |
| Haleon Plc (ADR) \* † | 3587507 | 28700056 |
|  |  | 82381658 |
| **United States: 62.8%** |  |  |
| AbbVie, Inc. | 199412 | 32226973 |
| AmerisourceBergen Corp. | 154000 | 25519340 |
| Bausch Health Cos, Inc. \* | 657496 | 4129075 |
| Bristol-Myers Squibb Co. | 364550 | 26229372 |
| Catalent, Inc. \* | 264103 | 11887276 |
| Elanco Animal Health, Inc. \* | 618589 | 7559158 |
| Eli Lilly & Co. | 88009 | 32197213 |

---

---

| | | |
|:---|:---|:---|
| | **Number<br>of Shares** | **Value** |
| **United States (continued)** |  |  |
| Jazz Pharmaceuticals Plc \* | 110006 | $17525056 |
| Johnson & Johnson | 273748 | 48357584 |
| McKesson Corp. | 68553 | 25715601 |
| Merck & Co., Inc. | 285888 | 31719274 |
| Organon & Co. | 456242 | 12742839 |
| Patterson Companies, Inc. | 144712 | 4056277 |
| Perrigo Co. Plc | 225816 | 7698067 |
| Pfizer, Inc. | 579986 | 29718483 |
| Viatris, Inc. | 2259882 | 25152487 |
| Zoetis, Inc. | 175893 | 25777119 |
|  |  | 368211194 |
| **Total Common Stocks** <br> (Cost: $600,296,815) |  | 586004427 |
| **SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES ON LOAN: 5.0%** | **SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES ON LOAN: 5.0%** | **SHORT-TERM INVESTMENT HELD AS COLLATERAL FOR SECURITIES ON LOAN: 5.0%** |
| **Money Market Fund: 5.0%**<br> (Cost: $29,339,008) |  |  |
| State Street Navigator Securities Lending Government Money Market Portfolio | 29339008 | 29339008 |
| **Total Investments: 105.0%**<br> (Cost: $629,635,823) |  | 615343435 |
| **Liabilities in excess of other assets: (5.0)%** |  | (29153577) |
| **NET ASSETS: 100.0%** |  | $586189858 |

---

------

---

| | |
|:---|:---|
| **Definitions:** | **Definitions:** |
| ADR | American Depositary Receipt |

---

---

| | |
|:---|:---|
| **Footnotes:** | **Footnotes:** |
| \* | Non-income producing |
| † | Security fully or partially on loan. Total market value of securities on loan is $32,833,677. |

---

---

| | | |
|:---|:---|:---|
| **Summary of Investments by Sector<br><u>Excluding Collateral for Securities Loaned</u>** | **% of<br> Investments** | **Value** |
| Pharmaceuticals | 80.2% | $469786179 |
| Health Care Distributors | 9.4 | 55291219 |
| Biotechnology | 5.5 | 32226973 |
| Personal Products | 4.9 | 28700056 |
|  | 100.0% | $586004427 |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** VanEck ETF Trust

- **b. Investment Company Act file number:** 811-10325

- **c. CIK number of Registrant:** 0001137360

- **d. LEI of Registrant:** 549300ZLFKNTXC51ZN76

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 666 THIRD AVENUE, 9TH FLOOR

  - **City:** NEW YORK

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 212-293-2000

**Item A.2. Information about the Series.**

- **a. Name of Series:** VanEck Pharmaceutical ETF

- **b. EDGAR series identifier (if any):** S000034409

- **c. LEI of Series:** 5493008SDOYUHMC8LF44

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-09-30

- **b. Date as of which information is reported:** 2022-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $615644883.45

**Total Liabilities:** $29457101.68

**Net Assets:** $586187781.77

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000105867 | 8.79%                | 5.85%                | 1.13%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-889017.50              | $43254556.24                               |
| Month 2  | $3362172.10              | $27127572.13                               |
| Month 3  | $3144104.92              | $2775971.62                                |

### Schedule of Portfolio Investments

| Name                               | Title                                                                       | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Viatris Inc                        | Viatris Inc                                                                 | CUSIP: 92556V106<br>LEI: 254900ZZTSW7NL773X71 | Long             | EC               | CORP              | US        |   2259882 | NS      | $25152486.66  | 4.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Johnson & Johnson                  | Johnson & Johnson                                                           | CUSIP: 478160104<br>LEI: 549300G0CFPGEF6X2043 | Long             | EC               | CORP              | US        |    273748 | NS      | $48357584.20  | 8.25%             |  |  |  | No            |                  1 | On Loan: No      |
| Bausch Health Cos Inc              | Bausch Health Cos Inc                                                       | CUSIP: 071734107<br>LEI: B3BS7ACMDUWISF18KY76 | Long             | EC               | CORP              | CA        |    657496 | NS      | $4129074.88   | 0.70%             |  |  |  | No            |                  1 | On Loan: No      |
| AbbVie Inc                         | AbbVie Inc                                                                  | CUSIP: 00287Y109<br>LEI: FR5LCKFTG8054YNNRU85 | Long             | EC               | CORP              | US        |    199412 | NS      | $32226973.32  | 5.50%             |  |  |  | No            |                  1 | On Loan: No      |
| Takeda Pharmaceutical Co Ltd       | Takeda Pharmaceutical Co Ltd                                                | CUSIP: 874060205<br>LEI: 549300ZLMVP4X0OGR454 | Long             | EC               | CORP              | JP        |   1785206 | NS      | $27849213.60  | 4.75%             |  |  |  | No            |                  1 | On Loan: —       |
| State Street Global Advisors       | State Street Navigator Securities Lending Government Money Market Portfolio | CUSIP: 857492706<br>LEI: 5493008BJIBKQ5KTIF74 | Long             | STIV             | RF                | US        |  29245826 | NS      | $29245826.50  | 4.99%             |  |  |  | No            |                  1 | On Loan: No      |
| Zoetis Inc                         | Zoetis Inc                                                                  | CUSIP: 98978V103<br>LEI: 549300HD9Q1LOC9KLJ48 | Long             | EC               | CORP              | US        |    175893 | NS      | $25777119.15  | 4.40%             |  |  |  | No            |                  1 | On Loan: No      |
| GSK PLC                            | GSK PLC                                                                     | CUSIP: 37733W204<br>LEI: 5493000HZTVUYLO1D793 | Long             | EC               | CORP              | GB        |    711082 | NS      | $24987421.48  | 4.26%             |  |  |  | No            |                  1 | On Loan: No      |
| Novo Nordisk A/S                   | Novo Nordisk A/S                                                            | CUSIP: 670100205<br>LEI: 549300DAQ1CVT6CXN342 | Long             | EC               | CORP              | DK        |    232662 | NS      | $31488475.08  | 5.37%             |  |  |  | No            |                  1 | On Loan: No      |
| AstraZeneca PLC                    | AstraZeneca PLC                                                             | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    423218 | NS      | $28694180.40  | 4.90%             |  |  |  | No            |                  1 | On Loan: No      |
| Perrigo Co PLC                     | Perrigo Co PLC                                                              | CUSIP: 000000000<br>LEI: 549300IFOQS6R1QLY196 | Long             | EC               | CORP              | IE        |    225816 | NS      | $7698067.44   | 1.31%             |  |  |  | No            |                  1 | On Loan: No      |
| Sanofi                             | Sanofi                                                                      | CUSIP: 80105N105<br>LEI: 549300E9PC51EN656011 | Long             | EC               | CORP              | FR        |    547031 | NS      | $26492711.33  | 4.52%             |  |  |  | No            |                  1 | On Loan: No      |
| Organon & Co                       | Organon & Co                                                                | CUSIP: 68622V106<br>LEI: 549300AMCKY57OK2CO56 | Long             | EC               | CORP              | US        |    456242 | NS      | $12742839.06  | 2.17%             |  |  |  | No            |                  1 | On Loan: No      |
| Patterson Cos Inc                  | Patterson Cos Inc                                                           | CUSIP: 703395103<br>LEI: YM48Q2087CUE26GWEK09 | Long             | EC               | CORP              | US        |    144712 | NS      | $4056277.36   | 0.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Pfizer Inc                         | Pfizer Inc                                                                  | CUSIP: 717081103<br>LEI: 765LHXWGK1KXCLTFYQ30 | Long             | EC               | CORP              | US        |    579986 | NS      | $29718482.64  | 5.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Jazz Pharmaceuticals PLC           | Jazz Pharmaceuticals PLC                                                    | CUSIP: 000000000<br>LEI: 635400GAUMJCLEZRRV50 | Long             | EC               | CORP              | IE        |    110006 | NS      | $17525055.86  | 2.99%             |  |  |  | No            |                  1 | On Loan: No      |
| AmerisourceBergen Corp             | AmerisourceBergen Corp                                                      | CUSIP: 03073E105<br>LEI: AI8GXW8LG5WK7E9UD086 | Long             | EC               | CORP              | US        |    154000 | NS      | $25519340.00  | 4.35%             |  |  |  | No            |                  1 | On Loan: No      |
| Haleon PLC                         | Haleon PLC                                                                  | CUSIP: 405552100<br>LEI: 549300PSB3WWEODCUP19 | Long             | EC               | CORP              | GB        |   3587507 | NS      | $28700056.00  | 4.90%             |  |  |  | No            |                  1 | On Loan: —       |
| McKesson Corp                      | McKesson Corp                                                               | CUSIP: 58155Q103<br>LEI: 549300WZWOM80UCFSF54 | Long             | EC               | CORP              | US        |     68553 | NS      | $25715601.36  | 4.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Teva Pharmaceutical Industries Ltd | Teva Pharmaceutical Industries Ltd                                          | CUSIP: 881624209<br>LEI: 549300BAFGM4RC74ZJ94 | Long             | EC               | CORP              | IL        |   2276701 | NS      | $20763513.12  | 3.54%             |  |  |  | No            |                  1 | On Loan: No      |
| Elanco Animal Health Inc           | Elanco Animal Health Inc                                                    | CUSIP: 28414H103<br>LEI: 549300SHPNDCE059M934 | Long             | EC               | CORP              | US        |    618589 | NS      | $7559157.58   | 1.29%             |  |  |  | No            |                  1 | On Loan: No      |
| Novartis AG                        | Novartis AG                                                                 | CUSIP: 66987V109<br>LEI: 5493007HIVTX6SY6XD66 | Long             | EC               | CORP              | CH        |    317655 | NS      | $28817661.60  | 4.92%             |  |  |  | No            |                  1 | On Loan: No      |
| Merck & Co Inc                     | Merck & Co Inc                                                              | CUSIP: 58933Y105<br>LEI: 4YV9Y5M8S0BRK1RP0397 | Long             | EC               | CORP              | US        |    285888 | NS      | $31719273.60  | 5.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Eli Lilly & Co                     | Eli Lilly & Co                                                              | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |     88009 | NS      | $32197212.56  | 5.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Catalent Inc                       | Catalent Inc                                                                | CUSIP: 148806102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    264103 | NS      | $11887276.03  | 2.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Bristol-Myers Squibb Co            | Bristol-Myers Squibb Co                                                     | CUSIP: 110122108<br>LEI: HLYYNH7UQUORYSJQCN42 | Long             | EC               | CORP              | US        |    364550 | NS      | $26229372.50  | 4.47%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2023-01-30

**Name of Applicant:** VanEck ETF Trust

**Signature:** James Parker

**Name of Signer:** James Parker

**Title:** Assistant Treasurer